Oxaliplatin with high-dose leucovorin (LV) and 5-Fluorouracil (5FU) 48-hour infusion in pretreated metastatic colorectal cancer (FOLFOX6)

被引：0
|
作者：
Maindrault-Goebel, F
de Gramont, A
Louvet, C
Andre, T
Carola, E
Gilles-Amar, V
Izrael, V
Krulik, M
机构：
[1] Hop St Antoine, GERCOR, F-75012 Paris, France
[2] Hop Tenon, F-75020 Paris, France
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
173P
引用
收藏
页码：36 / 36
页数：1
相关论文
共 50 条
  • [11] A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer
    Rosati, G
    Rossi, A
    Reggiardo, G
    Manzione, L
    ONCOLOGY, 2002, 62 (03) : 209 - 215
  • [12] A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer
    Rosati, G
    Tucci, A
    Rinaldi, A
    Colarusso, D
    Pizza, C
    Reggiardo, G
    Manzione, L
    ONCOLOGY, 2004, 66 (05) : 371 - 378
  • [13] Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
    Kalbakis, K
    Kouroussis, C
    Kakolyris, S
    Mavroudis, D
    Souglakos, J
    Agelaki, S
    Vamvakas, L
    Christodoulakis, M
    Stylianou, K
    Georgoulias, V
    BRITISH JOURNAL OF CANCER, 2001, 85 (06) : 798 - 802
  • [14] Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
    K Kalbakis
    Ch Kouroussis
    S Kakolyris
    D Mavroudis
    J Souglakos
    S Agelaki
    L Vamvakas
    M Christodoulakis
    K Stylianou
    V Georgoulias
    British Journal of Cancer, 2001, 85 : 798 - 802
  • [15] Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma
    Beerblock, K
    Rinaldi, Y
    Andre, T
    Louvet, C
    Raymond, E
    Tournigand, C
    Carola, E
    Favre, R
    deGramont, A
    Krulik, M
    CANCER, 1997, 79 (06) : 1100 - 1105
  • [16] Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients
    Mini, E
    Pinto, C
    Angelelli, B
    Dentico, P
    Piana, E
    Nobili, S
    Gentile, AL
    Scicolone, S
    Mazzei, T
    Martoni, A
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [17] Dose intensity of oxaliplatin in 5-fluorouracil and leucovorin regimens in pretreated metastatic colorectal cancer.
    Jeong, KJ
    Oh, JM
    Choi, SK
    Oh, D
    PHARMACOTHERAPY, 2002, 22 (10): : 1356 - 1356
  • [18] A Multicenter Phase-II Study of 5-FU, Leucovorin and Oxaliplatin (FOLFOX6) in Patients with Pretreated Metastatic Colorectal Cancer
    Kato, Ken
    Inaba, Yoshitaka
    Tsuji, Yasushi
    Esaki, Taito
    Yoshioka, Akira
    Mizunuma, Nobuyuki
    Mizuno, Toshiro
    Kusaba, Hitoshi
    Fujii, Hirohumi
    Muro, Kei
    Shimada, Yasuhiro
    Shirao, Kuniaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (01) : 63 - 68
  • [19] A simplified bi-monthly regimen with leucovorin (LV) and 5-Fluorouracil (5FU) for metastatic colorectal cancer (MCRC)
    Tournigand, C
    de Gramont, A
    Louvet, C
    Andre, T
    Carola, E
    Gilles-Amar, V
    Maindrault-Goebel, F
    Lotz, JP
    Molitor, JL
    ANNALS OF ONCOLOGY, 1998, 9 : 40 - 40
  • [20] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345